OWC Pharmaceutical Research Corp.

Equities

OWCP

US67109N1081

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 09:30:00 2024-05-01 am EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2021	OWC Pharmaceutical Research Corp. Announces Resignation of David Kugelman as the Sole Director	CI
2021	Discover Growth Enters into Agreement with OWC Pharmaceutical	CI

Owc Pharmaceutical Research Corp. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 15, 2019 at 02:26 pm EDT

OWC Pharmaceutical Research Corp. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced net loss was USD 1.000 million compared to USD 977,000 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp. Announces Resignation of David Kugelman as the Sole Director	21-08-25	CI
Discover Growth Enters into Agreement with OWC Pharmaceutical	21-06-21	CI
Discover Growth Provides Information to Shareholders of OWC Pharmaceutical	21-03-30	CI
OWC Pharmaceutical Research Corp. Announces Board Changes	21-03-05	CI
Discover Growth Seeks to Replace Directors at OWC Pharmaceutical	21-03-05	CI
Discover Growth Intends to Vote to Replace the Board of OWC Pharmaceutical	21-02-25	CI
OWC Pharmaceutical Research Corp. Announces the Resignation of Shmuel De-Saban from the Board of Directors	20-11-03	CI
OWC Pharmaceutical Research Corp. Announces New Distribution Agreement with Can It Industries	20-09-14	CI
OWC Pharmaceutical Research Corp. Announces Board Changes	20-06-26	CI
OWC Pharmaceutical Research Corp. Appoints Shmuel De-Saban as Chief Financial Officer of the Company, Effective July 1, 2020	20-06-26	CI
OWC Pharmaceutical Research Corp. Announces Executive Changes	20-06-24	CI
OWC Pharmaceutical Research Corp. Appoints Ziv Turner to the Board of Directors	20-06-24	CI
OWC Pharmaceutical Research Corp. and One World Cannabis Ltd. Announces Board Changes	20-03-18	CI
OWC Pharmaceutical Research Corp. Announces Management Changes	20-03-09	CI
Owc Pharmaceutical Research Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-13	CI
Stenocare A/S and Owc Pharmaceutical Research Corp. Enters into Partnership to Develop Advanced Medical Cannabis Products	19-11-13	CI
Owc Pharmaceutical Research Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-13	CI
OWC Pharmaceuticals Research Receives Permit for Cannabis Based Ointment Efficacy Trial	19-08-05	CI
OWC Pharmaceuticals Research Corp. Receives Approval from Israeli Medical Cannabis Agency	19-07-24	CI
Owc Pharmaceutical Research Corp. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-15	CI
OWC Pharmaceutical Research Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-01	CI
OWC Pharmaceutical Research Corp. to Collaborate with Sourasky Medical Center in Tel Aviv for a Safety Study on its Cannabis-Based Tablets	19-03-27	CI
Owc Pharmaceutical Research Corp. Announces Executive Changes	19-02-04	CI
OWC Pharmaceutical Research Corp. Reports Positive Phase 1 Safety Data for its Medical Grade Cannabis MSG Ointment for the Treatment of Skin Diseases	19-01-29	CI
OWC Pharmaceutical Research Corp. Reports the Successful Production of Cannabinoid-Enriched Sublingual Disintegrating Tablet	18-12-18	CI

Chart OWC Pharmaceutical Research Corp.

Duration

Period

More charts

Company Profile

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company's Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
OWC PHARMACEUTICAL RESEARCH CORP.	0.00%	497
SARTORIUS AG	-14.68%	18.88B
QUIDELORTHO CORPORATION	-42.33%	2.84B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+17.00%	1.85B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-0.51%	1.66B
BIOTAGE AB	+27.15%	1.26B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-13.90%	989M
CONTEC MEDICAL SYSTEMS CO.,LTD	-21.76%	896M
REVENIO GROUP OYJ	-2.72%	757M
VAREX IMAGING CORPORATION	-23.95%	633M

Medical Diagnostic & Testing Equipment